Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Dorisca Research Consulting LLC

Neither a doctor nor a teaching hospital

Research payments

$1,170,039

549 payments

Through program year 2025, Dorisca Research Consulting LLC is reported as receiving $1,170,039 in research payments, across 549 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $308,530 113
2024 Research $364,595 199
2023 Research $212,653 90
2022 Research $57,639 49
2021 Research $107,255 34
2020 Research $68,309 26
2019 Research $51,058 38

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $389,994 303 payments
  2. Regeneron Pharmaceuticals, Inc. $206,825 129 payments
  3. Eli Lilly and Company $190,332 14 payments
  4. Pfizer Inc. $144,619 26 payments
  5. ITI, Inc. $98,750 31 payments
  6. Incyte Corporation $83,393 25 payments
  7. Arena Pharmaceuticals, Inc. $26,300 14 payments
  8. Argenx US, Inc. $15,500 5 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $14,000 1 payment
  10. Genzyme Corporation $325 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) $213,011 232 payments
  2. An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis $206,825 129 payments
  3. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease $92,783 4 payments
  4. Iti-007-602 $85,750 30 payments
  5. The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. $83,393 25 payments
  6. A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis $70,726 4 payments
  7. A Phase 2 Randomized Doubleblind Placebocontrolled Study to Investigate the Efficacy and Safety of Pf07275315 and Pf07264660 in Adult Participants With Moderatesevere Atopic Dermatitis $69,023 11 payments
  8. A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult and Adolescent Participants With Non Segmental Vitiligo $42,586 8 payments
  9. Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) $37,267 30 payments
  10. An Open-Label, Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis Previously Treated With Dupilumab $32,631 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record